Dural Arteriovenous Fistulas Treatment Market is Expected to Grow at a CAGR over ~ 6.60% from 2022 to 2030

Pune, India, Nov, 2022/MRFR Press Release/- Market Research Future has a half cooked research report on the global dural arteriovenous fistulae treatment market.

Market Highlights

Dural arteriovenous fistula is an abnormal connection between an artery and a vein. Any organ of the body can suffer from fistula. The brain is bounded by a tough fibrous cover called dura mater or dura. When a fistula forms between an artery and a vein within the dura, it is called brain dural fistula.

According to Migraine Research Foundation, migraine was the 3rd most prevalent illness in the world in 2014. The prevalence of migraine is very high in the US, which is nearly 1 in 4 people. Moreover, 18% of American women, 6% of men, and 10% of children experience migraines. Mostly migraine occurs at the age of 25-55.

Increasing prevalence of neurological disorder such as epilepsy and migraine leads to dural arteriovenous fistulae, and increasing investment in biotechnology and pharmaceutical industries in R&D drive the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology projected to fuel the market growth during the forecast period. However, high cost of the treatment may slow the market growth in the same period.

The global dural arteriovenous fistulae treatment market is expected to grow at a CAGR of ~ 6.60 % during the forecast period 2022-2030.

Regional Analysis

The Americas dominates the global dural arteriovenous fistulae treatment market owing to the presence of huge patient population with brain injury and neurological disorder such as depression, epilepsy, and migraine, high healthcare spending, and increasing government support for research & development.

Europe holds the second largest share of the global dural arteriovenous fistulae treatment market. The increasing focus of various government agencies on treating epilepsy, depression, and heart attacks expected to have a positive impact on the growth of the market over the assessment period. Additionally, growing public awareness may boost the adoption of these devices in the European market.

Asia Pacific is the fastest growing dural arteriovenous fistulae treatment market across the globe. In this region, Japan holds the major share of the regional market due to availability of technology and huge healthcare spending. Rapidly developing economy, increasing healthcare expenditure, and government initiatives for research & development will drive the market in China and India over the assessment period.  Furthermore, increasing patient population in India estimated to generate various new opportunities for the growth of the market in the given period.

The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East and African market. Whereas, the African region is expected to witness a moderate growth over the forecast period.

Segmentation

The global dural arteriovenous fistulae treatment market is segmented on the basis of type, treatment, and end user.

On the basis of type, the market is segmented into type I, type II, and type III.

On the basis of application, the market is segmented into surgery, stereotactic radiosurgery, embolization, and others.

On the basis of end user, the market is segmented into hospitals & clinics, ambulatory surgical centers, and others.

Key Players

Some of key the players in the market are BD (U.S.), Medtronic (U.S.), B. Braun Melsungen AG (Germany), Cook (U.S.), Teleflex Incorporated (U.S.), Fresenius Medical Care AG & Co. KGaA (Germany), NxStage Medical, Inc.(U.S.), and Poly Medicure Limited.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of Dural Arteriovenous Fistulas Treatment Market Research Report